End of Research Term. At the end of the Research Term, (a) neither CRISPR nor Vertex will have an obligation to perform any additional activities under any Research Plan and (b) CRISPR’s obligations and Vertex’s rights under this Agreement with respect to any Vertex Target that has not been designated as a Collaboration Target will terminate and the Vertex Target list will be dissolved. For clarity, the expiration of the Research Term will not affect Vertex’s rights or CRISPR’s obligations with respect to any Collaboration Target for which Vertex has exercised its Option as provided in Section 4.1 or for which the Option Deadline has not occurred.
End of Research Term. The Research Term will commence on the -------------------- Effective Date and, unless this Agreement is sooner terminated as provided in Section 12.2, 12.3, 12.5 or 12.7, will continue until the 5 year anniversary thereof; provided, however, that Glaxo's obligations to pay Research Fees to MEGABIOS under Article III shall survive any termination of this Agreement, except termination by Glaxo under Section 12.7 or by MEGABIOS under Section 12.5(b). ARTICLE XIII - ASSIGNMENT -------------------------
End of Research Term. The Research Term will commence on the Effective -------------------- Date and, unless this Agreement is sooner terminated as provided in Section 12.2, 12.3, 12.5, or 12.7, shall expire as of April 1, 1997; provided, however, that Glaxo's obligations to pay Research Fees to MEGABIOS under Article III shall survive any termination of this Agreement, except termination by Glaxo under Section 12.7.
5. A new Article 16 shall be added to read as follows:
ARTICLE XVI - POST RESEARCH PERIOD DEVELOPMENT SERVICES ------------------------------------------------------- After the end of the Research Term, Glaxo shall have the option to enter into discussions with MEGABIOS for the performance of consulting services with respect to the development of Cystic Fibrosis Agents and MEGABIOS agrees to enter into good faith negotiations with Glaxo to agree upon reasonable terms and conditions for the provision of such services and to provide such services pursuant to such agreed-upon terms and conditions.
End of Research Term. Upon the expiration of the Research Term, (a) Regulus will not be obligated to continue to perform work under the Research Program; (b) Sanofi may not designate any additional (or substituted) Collaboration Targets under Section 3.6; and (c) subject to Regulus’ obligations under Section 2.3, Regulus will […***…] any data generated under the R&D Plan for any microRNA that is not a Collaboration Target, including any microRNA Compound antagonizing or mimicking such microRNA.
End of Research Term. At the end of the Research Term, this Agreement will terminate automatically if Biogen Idec has not designated at least one (1) Development Compound, unless (i) the Parties have previously mutually agreed on activities aimed at advancing a Lead Compound to designation as a Development Compound and the mutually agreed plan for such activities extends beyond the end of the Research Term, or (ii) the Parties mutually agree at least [***] prior to the expiration of the Research Term to continue the research for a specified additional period of time and agree on all relevant matters relating to such extension including, but not limited to, the Parties’ respective rights and obligations with regard to the ongoing research, a budget for such ongoing research and the Parties’ respective monetary obligations with regard to such budget. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Execution Version
End of Research Term. At the end of the Research Term, (i) neither Isis nor Biogen Idec will have an obligation to perform any activities under the Core Research Program or the Neurological Disease Research Program; (ii) the High Interest Target List (including the ALS Targets) will be dissolved, and any Neurology Targets that have not been designated Collaboration Targets or Biogen Idec Alternate Modality Targets will no longer be Neurology Targets under this Agreement; (iii) Isis’ obligations and Biogen Idec’s rights under this Agreement with respect to such Neurology Targets and any ASOs targeting such Neurology Targets will then terminate; and (iv) at Isis’ request, Biogen Idec will provide to Isis any data generated under the Core Research Program and the Neurological Disease Research Program and licensed to Isis under Section 4.3.2. For clarity, the expiration of the Research Term will not affect Biogen Idec’s rights or Isis’ obligations with respect to Collaboration Programs or Biogen Idec Alternate Modality Programs under this Agreement, including, in the case of Collaboration Programs, Isis’ obligation under Section 1.10.1 to use Commercially Reasonable Efforts to identify a Development Candidate for each applicable Collaboration Program.
End of Research Term. Upon the expiration of the Research Term, any gene targets in the Target Pool that are not Selected Gene Targets will no longer be considered a Collaboration Gene Target and Isis’ obligations under this Agreement with respect to such gene targets (including but not limited to Section 2.3) will terminate. In addition, within [***] following the end of the Research Term, if a Research Compound targeting a Selected Gene Target has not satisfied the Designation of a Compound as Clinical Candidate, then such Selected Gene Target will no longer be considered a Collaboration Gene Target. Isis’ obligations (including but not limited to Section 2.3) and OMI’s licenses under this Agreement with respect to such gene target and any ASOs targeting such gene target will then terminate, and, subject to Article 11, Isis will own any data generated under the R&D Plan for such gene target and any ASOs targeting such gene target. OMI will have the right to use any data generated under the R&D Plan for its own internal research purposes that are unrelated to any Discontinued Products.
End of Research Term. At the end of the Research Term, (a) neither Ionis nor Biogen will have an obligation to perform any further activities under the Core Research Program; (b) if requested by Biogen, Ionis will complete all activities not yet completed under any ongoing Target Sanction Plans, and shall deliver to the Neurology JRC for review as soon as reasonably practical thereafter (i) any outstanding Target Sanction Data Packages, once completed, or (ii) where the activities under any Target Sanction Plan are not successful, the data and results generated by Ionis in completing the activities under each such Target Sanction Plan to the extent not already provided to Biogen; (c) the High Interest Target List will be dissolved except, solely for those High Interest Targets that achieved Target Sanction and for which Ionis has not delivered the deliverables required under subclauses (b)(i) and (b)(ii) of this Section 1.7, the High Interest Target List will dissolve after the expiration or exercise of Biogen’s right to designate such targets as Collaboration Targets; (d) if one or more Strategies directed to one or more High Interest Targets have not been designated as Collaboration Programs (such that such High Interest Targets are not Collaboration Targets at such time) on or before the Collaboration Program Final Deadline under Section 1.3 or the Ionis Collaboration Program Designation Date under Section 1.4, then such targets will no longer be Neurology Targets under this Agreement and Ionis’ obligations and Biogen’s rights under this Agreement with respect to such targets and any ASOs targeting such targets will then terminate; (e) at Ionis’ request, Biogen will provide to Ionis the data generated under the Core Research Program and the Neurological Disease Research Program to the extent licensed to Ionis under Section 4.3.4 and not already provided to Ionis; and (f) upon Biogen’s request, Ionis will provide to Biogen the data generated under the Core Research Program and the Neurological Disease Research Program to the extent licensed to Biogen under Section 4.3.3 and not already provided to Biogen. For clarity, the expiration of the Research Term will not affect Biogen’s rights or Ionis’ obligations with respect to Collaboration Targets or the identification of Development Candidates for Collaboration Programs under this Agreement.
End of Research Term. Subject to Sections 5.13(b), the Research Term shall end on the expiration of the Fifth Contract Year.
End of Research Term. At the end of the Research Term (or, with respect to clauses (a), (d) and (e) in this Section 1.9, the earlier termination of the Core Research Program), (a) neither Ionis nor Biogen will have an obligation to perform any activities under the Core Research Program or the Neurological Disease Research Program, (b) the High Interest Target List (including the ALS Targets) will be dissolved, and any Neurology Targets that have not been designated Collaboration Targets or Biogen Alternate Modality Targets will no longer be Neurology Targets under this Agreement, (c) Ionis’ obligations and Biogen’s rights under this Agreement with respect to such Neurology Targets and any ASOs targeting such Neurology Targets will then terminate, (d) to the extent not previously provided to Ionis during prior meetings of the Neurology II JRC, at Ionis’ reasonable request, Biogen will provide to Ionis any data generated under the Core Research Program and the Neurological Disease Research Program and licensed to Ionis under Section 4.3.4 and (e) to the extent not previously provided to Biogen during prior meetings of the Neurology JRC, at Biogen’s reasonable request, Ionis will provide to Biogen any data generated under the Core Research Program and the Neurological Disease Research Program and licensed to Biogen under Section 4.3.3. For clarity, the expiration of the Research Term will not affect Biogen’s rights or Ionis’ obligations with respect to Programs under this Agreement, including, in the case of Collaboration Programs, Ionis’ obligation under Section 1.10.1 to use Commercially Reasonable Efforts to identify a Development Candidate for each applicable Collaboration Program.
